|
Name |
Company |
Description |
|
Phase III |
||
|
Aplidin® (plitidepsin) |
PharmaMar, SA |
Marine-derived antitumor agent being evaluated in combination with dexamethasone (dex) in a trial being conducted in the US, Europe, and Australia, which has completed enrollment LEARN MORE |
|
Denosumab (AMG 162) |
Amgen |
Human monoclonal antibody that targets the receptor activator of nuclear factor kappa B ligand (RANKL) and inhibits bone destruction; approved as Xgeva® for use in bone disease in solid tumors and as Prolia® for osteoporosis in women after menopause |
|
Elotuzumab (HuLuc63; humanized anti-CS1 monoclonal antibody) |
Bristol-Myers Squibb/Abbott |
Monoclonal antibody that binds to CS1, a cell surface protein that is highly expressed on myeloma cells; being evaluated in combination with Revlimid-dex in two phase III studies in relapsed and previously untreated patients, as well as alone and with other agents in early-stage trials LEARN MORE |
|
Ixazomib citrate (MLN9078) |
Millennium: The Takeda Oncology Company |
Oral second-generation proteasome inhibitor; being evaluated alone and in combination with several other agents in relapsed and/or refractory myeloma; a phase III trial in combination with Revlimid-dex is currently enrolling; also being evaluated in newly diagnosed disease in combination with MP, and in combination with Revlimid-dex in a phase II study being facilitated by the MMRC; being evaluated in combination with dex for high-risk smoldering myeloma and in combination with Revlimid as maintenance therapy. LEARN MORE |
|
Masitinib (AB1010) |
AB Science |
Oral anticancer agent (tyrosine kinase inhibitor) being evaluated in combination with Velcade-dex in a phase III study being conducted in the US and Europe |
|
Panobinostat (LBH589) |
Novartis |
Deacetylase (DAC) inhibitor; being evaluated in combination with other agents, including Velcade-dex in a phase III study (enrollment completed), and |
|
Zolinza® (vorinostat, SAHA [suberoylanilide hydroxamic acid]) |
Merck |
Histone deacetylase (HDAC) inhibitor, FDA-approved for cutaneous T-cell lymphoma, that has shown activity in relapsed and refractory myeloma; phase III VANTAGE 088 study in combination with Velcade completed, with initial results showing reduced risk of disease progression with the combination over Velcade alone; although Merck is not continuing development of Zolinza in myeloma, it is still being evaluated in combination with other agents in early-stage clinical trials, and could potentially be used off-label. LEARN MORE |
|
Phase II |
||
|
Alisertib (MLN8237) |
Millennium: The Takeda Oncology Company |
Novel agent (Aurora A kinase inhibitor) being evaluated in combination with Velcade in a study being facilitated by the MMRC; Phase I results show the combination is active despite the lack of a steroid |
|
AT7519 (AT7519M) |
Astex Therapeutics |
Cyclin-dependent kinase (CDK) inhibitor being evaluated alone and combination with Velcade in a study being facilitated by the MMRC |
|
ARRY-520 |
Array BioPharma |
Agent that inhibits kinesin spindle protein (KSP); being evaluated alone, as well as in combination with Kyprolis, and with Velcade-dex in a study being facilitated by the MMRC; initial results with Kyprolis show a manageable side effect profile and early signs of activity in patients no longer responding to Velcade |
|
Bexxar® (iodine I 131 tositumomab) |
GlaxoSmithKline |
FDA-approved radiolabeled monoclonal antibody directed against CD20, a marker found on B cells and on some myeloma cells in 13% to 22% of patients; objective responses seen, particularly in patients with CD20-positive disease |
|
BHQ880 |
Novartis |
Monoclonal antibody (anti-DKK1) being evaluated in patients with untreated myeloma and impaired kidney function, as well as patients with high-risk smoldering myeloma (SMM; enrollment completed; the agent increased bone strength in 60% of patients) |
|
BT-062 |
Biotest AG |
Anti-CD138 monoclonal antibody/cytotoxic agent compound that has demonstrated activity in early testing; being evaluated alone and in combination with Revlimid-dex |
|
Daratumumab (HuMax-CD38) |
Genmab |
Human monoclonal antibody that targets the CD38 molecule, which is highly expressed on the surface of myeloma cells; being evaluated alone and in combination with Revlimid-dex and with Velcade-dex (trial set to begin); preliminary results show some evidence of single-agent activity |
|
Delanzomib (CEP-18770) |
Cephalon, a subsidiary of Teva Pharmaceuticals |
Proteasome inhibitor; being investigated alone and in combination with Revlimid; studies have completed enrollment; initial Phase I safety data show a lack of significant peripheral neuropathy, but skin toxicity was seen with twice-a-week dosing |
|
Dinaciclib (SCH 727965, MK-7965) |
Merck/Ligand Pharmaceuticals |
Cyclin-dependent kinase (CDK) inhibitor; being evaluated alone (completed enrollment; potential anti-myeloma activity observed) and in combination with Velcade-dex in a Phase I trial |
|
Ibrutinib (PCI-32765) |
Pharmacyclics |
Anticancer agent (Bruton’s tyrosine kinase inhibitor) that targets B cells; has shown promising results in treating another hematologic cancer (chronic lymphocytic leukemia, CLL) |
|
Imetelstat (GRN163L) |
Geron Corporation |
Telomerase inhibitor that has been shown in vitro to induce apoptosis and inhibit myeloma cell growth |
|
IPH2101 (IPH21, IPH2102) |
Innate Pharma/Bristol-Myers Squibb |
Monoclonal antibody (anti-KIR) that enhances killing of myeloma cells by natural killer (NK) cells; being evaluated alone and in combination with other agents, as well as in smoldering myeloma; studies have completed enrollment. Interim results of a Phase I trial in combination with Revlimid are promising |
|
KW-2478 |
Kyowa Hakko Kirin Co., Ltd. |
Heat-shock protein (HSP) 90 inhibitor being evaluated in combination with Velcade (completed enrollment) |
|
Milatuzumab (IMMU-110) and milatuzumab-doxorubicin conjugate (hLL1-DOX) |
Immunomedics |
Humanized monoclonal antibody directed against the CD74 protein found on B cells and myeloma cells; being evaluated as a therapeutic monoclonal antibody (enrollment completed) and an antibody-drug conjugate |
|
Palbociclib (PD-0332991) |
Pfizer |
Kinase inhibitor being evaluated in combination with Velcade and dexamethasone; enrollment completed |
|
Siltuximab (CNTO-328) |
Janssen Biotech, Inc. |
Anti-IL-6 monoclonal antibody being evaluated in patients with high-risk smoldering myeloma in a phase II trial, and in combination with Revlimid-Velcade-dex in transplant-eligible newly diagnosed myeloma in a phase I trial (enrollment completed) |
|
Tabalumab (LY2127399) |
Eli Lilly |
Antibody directed against a protein that activates B cells; being tested in combination with Velcade-dex; results of a Phase I study show the combination to be safe, with efficacy demonstrated |
|
TBL-12 |
Unicorn Pacific Corporation |
Sea cucumber extract that displays immunomodulatory properties; being evaluated in untreated, asymptomatic myeloma (enrollment completed) |
|
Tivantinib (ARQ 197) |
ArQule/National Cancer Institute |
Anti-cancer agent that inhibits an enzyme (c-Met) involved in many cancer cell activities |
|
Treanda® (bendamustine hydrochloride; known as Ribomustin® in Germany) |
Cephalon, a subsidiary of Teva Pharmaceuticals |
Alkylating agent FDA-approved for use in treating leukemia and lymphoma; approved in Germany for use in myeloma; being evaluated as part of various combination therapies for use in newly diagnosed and relapsed and/or refractory disease, including a study in combination with Revlimid-dex that is being facilitated by the MMRC LEARN MORE |
|
Vidaza® (azacitidine) |
Celgene Corporation |
Cytotoxic drug FDA-approved for the treatment of myelodysplastic syndromes (MDS) being evaluated alone and in combination with other agents |
|
Phase I |
||
|
ALT-801 |
Altor Bioscience Corporation |
Anti-tumor immunotherapeutic protein |
|
Amrubicin |
Celgene Corporation |
Chemotherapy drug approved in Japan for small-cell lung cancer; being evaluated in combination with Revlimid-dex; initial results show no unexpected toxicities |
|
BI-505 |
BioInvent International AB |
Monoclonal antibody directed against ICAM-1, a protein that enables immune cells to migrate from the blood into tissues; enrollment completed; preliminary results show a favorable safety profile and evidence of disease stabilization |
|
BMS-936564 (MDX-1338) |
Bristol-Myers Squibb |
Monoclonal antibody directed against a cell marker (CXCR4) normally found on immune cells and in increased levels in various cancer cells; induces tumor cell apoptosis; being evaluated alone and in combination with Revlimid-dex or Velcade-dex |
|
Cometriq™ (cabozantanib, XL184) |
Exelixis, Inc |
Novel agent (tyrosine kinase inhibitor) that reduces tumor growth, metastasis, and growth of blood vessels; FDA approved to treat a form of thyroid cancer |
|
CUDC-907 |
Curis, Inc. |
Novel agent (phosphoinositide 3-kinase [PI3K] and histone deacetylase [HDAC] inhibitor) that inhibits cancer cell survival and growth |
|
CX-4945 |
Cylene Pharmaceuticals |
Oral protein kinase (CK2) inhibitor |
|
DFRF4539A |
Genentech |
Monoclonal antibody |
|
DKN-01 |
Dekkun Corporation |
Monoclonal antibody (anti-DKK1); being evaluated in combination with Revlimid-dex in a trial that is set to begin |
|
Erivedge® (vismodegib, GDC-0449) |
Genentech |
Synthetic Hedgehog pathway inhibitor being evaluated in patients with high-risk myeloma following stem cell transplant, recently FDA approved for use in treating a type of skin cancer (basal cell carcinoma) |
|
Folotyn® (pralatrexate) |
Allos Therapeutics, a subsidiary of Spectrum Pharmaceuticals |
Chemotherapy drug approved for use in peripheral T-cell lymphoma that is being evaluated in combination with Velcade |
|
Ganetespib (STA-9090) |
Synta Pharmaceuticals |
Synthetic, small molecule inhibitor of heat shock protein 90 (Hsp90); being evaluated with and without Velcade in a trial being facilitated by the MMRC |
|
GSK2110183 |
GlaxoSmithKline |
Oral anticancer agent (AKT inhibitor) being evaluated in combination with Velcade-dex in a trial being facilitated by the MMRC |
|
LGH447 |
Novartis |
Oral anti-cancer agent |
|
Linsitinib (ASP7487, OSI-906) |
Astellas Pharma Inc. |
Agent that triggers cancer cell death (insulin-like growth factor-1 [IGF-1] receptor inhibitor); MMRC-facilitated trial set to begin in Canada evaluating the agent in combination with Velcade-dex |
|
Lorvotuzumab mertansine (IMGN901, BB-10901) |
ImmunoGen |
Monoclonal antibody directed against the CD56 marker found on myeloma cells, coupled with a cancer drug; being evaluated in combination with Revlimid-dex (completed enrollment); activity demonstrated, including in patients previously treated with IMiDs +/- Velcade |
|
Marizomib (NPI-0052) |
Nereus Pharmaceuticals |
Novel proteasome inhibitor being evaluated in an MMRC-facilitated study that has shown promising early safety data LEARN MORE |
|
MLN0128 |
Millennium: The Takeda Oncology Company |
Oral kinase inhibitor; enrollment completed |
|
MLN4924 |
Millennium: The Takeda Oncology Company |
Novel agent (inhibitor of Nedd8 activating enzyme); enrollment completed |
|
Oncolytic measles virus (MV-NIS) |
Mayo Clinic |
Genetically engineered measles virus being administered with or without cyclophosphamide |
|
Oprozomib (ONX 0912) |
Onyx Pharmaceuticals, Inc. |
Oral proteasome inhibitor that is similar to Kyprolis |
|
PRLX 93936 |
Prolexys Pharmaceuticals |
Novel agent that targets the RAS protein |
|
PVX-410 |
OncoPep, Inc. |
Therapeutic cancer vaccine targeted against four proteins found on the surface of myeloma cells; being tested in asymptomatic (smoldering) myeloma |
|
Rocilinostat (ACY-1215) |
Acetylon Pharmaceuticals, Inc. |
Oral histone deacetylase (HDAC) inhibitor being evaluated alone and in combination with Velcade-dex or Revlimid-dex |
|
SAR650984 |
Sanofi |
Antibody directed against the CD38 marker on certain cancer cells; being evaluated in combination with Revlimid |
|
SNS01-T |
Senesco Technologies, Inc. |
Anticancer agent targeted to B cells that induces apoptosis |
|
TH-302 |
Threshold Pharmaceuticals |
Anticancer drug that is converted to its active form in areas where there is low oxygen (hypoxia), such as within tumors or in the bone marrow where myeloma cells are found; being evaluated alone and in combination with Velcade |
 |
|
Contact Us | Corporate Supporters | Terms of Use | Privacy Policy Copyright © 2013 Multiple Myeloma Research Foundation |
